...
首页> 外文期刊>International Journal of Surgery Case Reports >Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
【24h】

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)

机译:病例报告:右肝切除术中术中血栓形成心脏骤停,涉及在术中细胞挽救(ICS)中使用局部止血剂并给予重组活化的VII因子(rFVIIa)

获取原文
           

摘要

Introduction In modern surgical era, local haemostatic agents and blood components such as recombinant activated factor VII (rFVIIa) have expanded surgeons’ armamentarium in controlling “surgical” and “nonsurgical bleeding”. We report a case of intraoperative thrombosis and cardiac arrest involving use of local haemostatic agent in intraoperative cell salvage and rFVIIa administration in extended right hepatectomy. Presentation of case A 46-year-old lady underwent extended right hepatectomy using cardiopulmonary bypass (CPB) and autotransfusion with ICS for metastatic gastrointestinal stromal tumour. She became extremely coagulopathic following weaning of CPB despite an array of fluid and blood products replacements. Decision to administer rFVIIa as a measure to arrest bleeding was unsuccessful. Extensive systemic thrombosis occurred which resulted in cardiac arrest and mortality. Discussion The thromboembolic event was unclear but likely multifactorial. Two important hypotheses were the administration of rFVIIa and use of local haemostatic agent in ICS. Conclusion Reported incidence of thromboembolism with use of rFVIIa in refractory bleeding is variable. More randomised controlled trials are needed to ascertain the efficacy and safety profile of the haemostatic agent. At present, off-label use of rFVIIa should be guided by the risk:benefit profile on a case-to-case basis. The authors also feel strongly against the use of local haemostatic gel in conjunction with ICS due to potential systemic circulation of the thrombin.
机译:引言在现代外科时代,局部止血剂和血液成分(例如重组活化因子VII(rFVIIa))扩大了外科医生的军备库,以控制“外科手术”和“非外科手术出血”。我们报告一例术中血栓形成和心脏骤停,涉及在术中细胞抢救中使用局部止血剂以及在右肝切除术中应用rFVIIa。病例介绍一位46岁的女士接受了体外循环右肝切除术,使用了体外循环(CPB)和ICS自体输注治疗转移性胃肠道间质瘤。尽管CPB断奶了许多液体和血液产品替代品,但她变得极度凝固性。决定使用rFVIIa作为止血措施是不成功的。发生广泛的全身血栓形成,导致心脏骤停和死亡。讨论血栓栓塞事件尚不清楚,但可能是多因素的。两个重要的假设是rFVIIa的使用和ICS中局部止血剂的使用。结论报道的使用rFVIIa治疗难治性出血的血栓栓塞发生率是可变的。需要更多的随机对照试验来确定止血药的功效和安全性。目前,rFVIIa的标签外使用应根据个案的风险:获益情况进行指导。由于凝血酶的潜在全身循环,作者还强烈反对将局部止血凝胶与ICS结合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号